TFI International remains a strong buy with solid cash flow, strategic growth, and new buying opportunities amid a recovering ...

Northwest Pipe's growth is set to surge in FY25, with improving margins, strong order momentum, and favorable stock valuation ...

Torrid Holdings faces revenue challenges, e-commerce risks, and industry pressures. See here to know why we recommend a sell ...

CAVA's expansion boosts revenue, but slowing sales and high valuation raise concerns. Read here for an analysis of CAVA stock ...

Demand for private credit continues to surge, with projections suggesting it could hit $2.8 trillion by 2028. Read more here.

Omada Health shows strong growth and innovation in chronic care but remains unprofitable with valuation, churn. See why OMDA ...

Generate consistent income with Sixth Street Specialty (TSLX) stock's 8.9% yield and strong distribution coverage. Read here ...

More banks are racking up frequent losses, while the cumulative net loss at credit unions has jumped in recent periods.

AstraZeneca targets $80bn revenue by 2030, driven by oncology and new drugs, but faces patent risks and tough competition.

X Financial offers asymmetric upside with strong growth, stable asset quality, and a high ROE at a low valuation. Learn why ...

Aker ASA remains discounted to NAV, with steps like the Solstad IPO and Cognite's U.S. shift supporting value. See why AKAAF ...

Marubeni, backed by Buffett and strong fundamentals, stands out amid market uncertainty with growth, dividends, buybacks, and ...